Lactose
LACTOSEINDIALTD NSE
Lactose
HealthcareNSE: LACTOSEINDIALTD BSE: 524202 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹126 Cr
Volatility
Moderate
P/E Ratio
18.2
EBITDA
₹18.38 Cr
Return on Equity
8.79%
Debt to Equity
0.95
Book Value
₹51.46
EPS
₹6.44
52W High
₹136.7
52W Low
₹76.01
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is expected to give good quarter
- Company has delivered good profit growth of 34.8% CAGR over last 5 years
- Company's working capital requirements have reduced from 22.6 days to 18.1 days
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 11.3% over last 3 years.
- Promoters have pledged 26.1% of their holding.
Growth Rate
Revenue Growth
38.5% higher than
3Y
Net Income Growth
42.31% lower than
3Y
Cash Flow Change
-103% higher than
3Y
ROE
-39% lower than
3Y
ROCE
-25.68% lower than
3Y
EBITDA Margin (Avg.)
-28.43% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27.47 | 24.43 | 32.6 | 29.4 | 29.46 | 30.45 | 28.72 | 27.77 | 39.58 | 41.18 | 36.77 | 45.77 | 46.97 |
| Expenses | 23.7 | 21.04 | 26.88 | 23.28 | 23.88 | 25.44 | 25.75 | 24.36 | 35.11 | 35.92 | 33.71 | 40.75 | 40.9 |
| Operating Profit | 3.77 | 3.39 | 5.72 | 6.12 | 5.58 | 5.01 | 2.97 | 3.41 | 4.47 | 5.26 | 3.06 | 5.02 | 6.07 |
| OPM % | 13.72% | 13.88% | 17.55% | 20.82% | 18.94% | 16.45% | 10.34% | 12.28% | 11.29% | 12.77% | 8.32% | 10.97% | 12.92% |
| Other Income | 0.28 | 0.26 | 0.28 | 0.31 | 0.22 | 0.3 | 0.56 | 0.37 | 0.41 | 0.37 | 0.63 | 0.22 | 0.56 |
| Interest | 1.55 | 1.31 | 1.21 | 1.17 | 1.26 | 1.37 | 1.64 | 1.84 | 1.22 | 1.04 | 1.39 | 1.43 | 1.76 |
| Depreciation | 1.19 | 1.2 | 1.2 | 1.63 | 1.31 | 1.33 | 1.35 | 1.39 | 1.37 | 1.44 | 1.43 | 1.5 | 1.64 |
| PBT | 1.31 | 1.14 | 3.59 | 3.63 | 3.23 | 2.61 | 0.54 | 0.55 | 2.29 | 3.15 | 0.87 | 2.31 | 3.23 |
| Tax % | 26.72% | 28.95% | 27.02% | 33.88% | 29.72% | 22.22% | 59.26% | -18.18% | 34.5% | 31.11% | 40.23% | 18.61% | 26.93% |
| Net Profit | 0.96 | 0.81 | 2.63 | 2.4 | 2.27 | 2.03 | 0.22 | 0.64 | 1.5 | 2.16 | 0.53 | 1.88 | 2.37 |
| EPS in Rs | 0.76 | 0.64 | 2.09 | 1.91 | 1.8 | 1.61 | 0.17 | 0.51 | 1.19 | 1.72 | 0.42 | 1.49 | 1.88 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 34 | 36 | 31 | 41 | 40 | 35 | 46 | 66 | 114 | 116 | 163 | 171 |
| Expenses | 19 | 24 | 24 | 25 | 31 | 31 | 29 | 34 | 54 | 95 | 99 | 145 | 151 |
| Operating Profit | 5 | 10 | 11 | 6 | 10 | 9 | 6 | 12 | 11 | 19 | 17 | 18 | 19 |
| OPM % | 22% | 30% | 32% | 18% | 24% | 23% | 18% | 27% | 17% | 17% | 15% | 11% | 11% |
| Other Income | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| Interest | 3 | 4 | 4 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 6 | 5 | 6 |
| Depreciation | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 6 |
| PBT | 1 | 4 | 4 | -3 | 1 | 0 | -3 | 3 | 1 | 10 | 7 | 9 | 10 |
| Tax % | 42% | 28% | 36% | -52% | 33% | 30% | -24% | 23% | 18% | 30% | 25% | 30% | — |
| Net Profit | 0 | 3 | 3 | -1 | 1 | 0 | -2 | 2 | 1 | 7 | 5 | 6 | 7 |
| EPS in Rs | 0.59 | 3.17 | 2.87 | -1.32 | 0.71 | 0.07 | -2.17 | 1.95 | 0.96 | 5.39 | 4.1 | 4.81 | 5.51 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 9 | 10 | 10 | 10 | 10 | 11 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 7 | 12 | 17 | 22 | 24 | 24 | 24 | 27 | 28 | 35 | 46 | 52 |
| Borrowings | 39 | 37 | 34 | 38 | 36 | 39 | 46 | 41 | 38 | 39 | 57 | 62 |
| Other Liabilities | 25 | 26 | 24 | 13 | 11 | 10 | 7 | 10 | 22 | 14 | 18 | 56 |
| Total Liabilities | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 183 |
| Fixed Assets | 62 | 61 | 64 | 63 | 60 | 62 | 59 | 59 | 56 | 55 | 52 | 69 |
| CWIP | 1 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 0 | 0 | 10 | 0 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Assets | 15 | 21 | 20 | 19 | 20 | 22 | 25 | 30 | 45 | 46 | 71 | 114 |
| Total Assets | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 183 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 13 | 1 | 8 | 0 | 5 | 7 | 2 | 8 | 8 | 9 | 0 | 6 |
| Investing | -23 | 3 | -5 | -2 | -2 | -3 | -6 | -1 | -1 | -2 | -16 | -10 |
| Financing | 10 | -5 | -3 | 4 | -5 | -4 | 5 | -8 | -8 | -6 | 19 | 1 |
| Net Cash Flow | -1 | 0 | 0 | 3 | -2 | 1 | 1 | 0 | -1 | 1 | 3 | -4 |
| Free Cash Flow | -10 | 0 | 3 | -2 | 3 | 4 | -3 | 7 | 6 | 7 | -14 | -5 |
| CFO/OP | 255 | 18 | 74 | 15 | 58 | 80 | 34 | 68 | 70 | 50 | 5 | 37 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 96 | 91 | 63 | 62 | 64 | 67 | 90 | 69 | 49 | 68 | 75 |
| Inventory Days | 129 | 344 | 440 | 456 | 384 | 471 | 587 | 343 | 344 | 119 | 171 | 217 |
| Days Payable | 273 | 340 | 559 | 330 | 242 | 202 | 153 | 195 | 275 | 59 | 74 | 146 |
| Cash Conversion Cycle | -61 | 100 | -27 | 188 | 204 | 333 | 501 | 238 | 138 | 109 | 165 | 146 |
| Working Capital Days | -118 | -100 | -107 | 18 | 42 | 59 | 56 | 46 | 56 | 26 | 24 | 18 |
| ROCE % | 8% | 13% | 15% | 4% | 9% | 8% | 3% | 10% | 9% | 18% | 13% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Lactose insights
62 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Clarification On Significant Price Movement Of The Company''s Security
29 Apr - 29 Apr 2026 reply to BSE: no pending announcement behind price movement. 29 Apr - 29 Apr 2026 reply to BSE: no pending announcement behind price movement.
2
Clarification On Significant Price Movement Of The Company''s Security
29 Apr - 29 Apr 2026 reply to BSE: no pending announcement behind price movement. 29 Apr - 29 Apr 2026 reply to BSE: no pending announcement behind price movement.
3
Clarification sought from Lactose India Ltd
24 Apr - Exchange has sought clarification from Lactose India Ltd on April 24, 2026 with reference to significant movement in price, in order to ensure that investors … 24 Apr - Exchange has sought clarification from Lactose India Ltd on April 24, 2026 with reference to significant movement in price, in order to ensure that investors …
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Apr - Submitted Regulation 74(5) certificate for dematerialization status for quarter ended 31 March 2026. 13 Apr - Submitted Regulation 74(5) certificate for dematerialization status for quarter ended 31 March 2026.
5
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
30 Mar - Lactose (India) EOGM held 28 Mar 2026; all resolutions passed; scrutinizer report enclosed. 30 Mar - Lactose (India) EOGM held 28 Mar 2026; all resolutions passed; scrutinizer report enclosed.
Frequently Asked Questions about Lactose
What does Lactose (India) Ltd do?
Incorporated in 1991, Lactose (India) Ltd manufactures Pharmaceutical Products and carries out job work[1]
Where is Lactose (India) Ltd (524202) listed?
Lactose (India) Ltd trades as LACTOSEINDIALTD on the NSE and under code 524202 on the BSE.
Which sector does Lactose (India) Ltd belong to?
Lactose (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Lactose (India) Ltd?
Lactose (India) Ltd has a market capitalisation of ₹125.62 Cr, which places it in the Small Cap band.
What is the PE ratio of Lactose (India) Ltd?
Lactose (India) Ltd trades at a PE ratio of 18.20, on earnings per share of ₹6.44, against a book value of ₹51.46 per share.
What is the 52-week high and low of Lactose (India) Ltd?
Over the last 52 weeks Lactose (India) Ltd has traded between ₹76.01 and ₹136.7.
What is the Return on Equity (ROE) of Lactose (India) Ltd?
Lactose (India) Ltd reported a return on equity of 8.79%. Its debt-to-equity ratio is 0.95.
Company Information
Incorporated in 1991, Lactose (India) Ltd manufactures Pharmaceutical Products and carries out job work[1]
Website lactoseindialimited.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524202.md for Lactose (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.